Monoclonal antibodies for prophylaxis and therapy of infectious diseases

Expert Opinion on Emerging Drugs

Volumn 12, Issue 4, 2007, Pages 525-540

  Ter Meulen, Jan ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Antibiotic resistant bacteria; Emerging virus; Infectious disease; Monoclonal antibody

Indexed keywords

ALTASTAPH; AMPHOTERICIN B; AUROGRAB; BAVITUXIMAB; CIVACIR; EFUNGUMAB; ETI 204; HEPATITIS B ANTIBODY; HEPEX B; HGS 004; IMMUNOGLOBULIN; KB 001; KBPA 101; KD 247; LAMIVUDINE; MDX 006; MDX 066; MDX 1303; MDX 1388; MONOCLONAL ANTIBODY; MOTAVIZUMAB; OST 577; PAGIBAXIMAB; PALIVIZUMAB; PLACEBO; PRO 140; RABIES IMMUNOGLOBULIN; RAXIBACUMAB; STAPHVAX; TEFIBAZUMAB; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERONATE; WNIG; XTL 68; XTL 6865;

ANTIBIOTIC RESISTANCE; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS C; HOSPITAL COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INVASIVE CANDIDIASIS; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NONHUMAN; PROPHYLAXIS; REVIEW; SEPSIS; SEPTICEMIA; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC FACTORS; MYCOSES; VIRUS DISEASES;

EID: 36549038193     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.4.525     Document Type: Review

References (74)

1. TALBOT GH, BRADLEY J, EDWARDS JE Jr et al.: Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin. Infect. Dis. (2006) 42(5):657-668.
2. BAD BUGS, NO DRUGS: As antibiotic R&D stagnates, a public health crisis brews. Alexandria VA: infectious disease society of America (2004). •• Concise overview of the antibiotic resistance crisis and its medical and social implications.
3. PROJAN S: Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. (2003) 6:427-430. • Overview of reasons for the empty pipeline of antibacterial drugs.
4. CASADEVALL A, DADACHOVA E, PIROFSKI L-A: Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. (2004) 2(9):695-703.
5. KELLER MA, STIEHM RE: Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. (2000) 13(4):602-614. •• Concise review of historic attempts to treat infectious diseases by passive antibody therapy.
6. BAKER M: Upping the ante on antibodies. Nat. Biotech. (2005) 23(9):1065-1072.
7. CURNS AT, HOLMAN RC, SEJVAR JJ et al.: Infectious disease hospitalizations among older adults in the United States from 1990 through 2002. Arch. Intern. Med. (2005) 165(21):2514-2520.
8. WENZEL RP, EDMOND MB: The impact of hospital-acquired bloodstream infections. Emerg. Infect. Dis. (2001) 7(2):174-177.
9. WISPLINGHOFF H, BISCHOFF T, TALLENT SM: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004) 39(3):309-317.
10. COSGROVE SE, QI Y, KAYE KS et al.: The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. (2005) 26(2):166-174.
11. APPELBAUM PC: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. (2006) 12(Suppl. 1):16-23.
12. GIAMARELLOU H: Treatment options for multidrug-resistant bacteria. Expert Rev. Antiinfect Ther. (2006) 4(4):601-618.
13. ALANIS AJ: Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. (2005) 36(6):697-705.
14. MWINTSHI K, BRENNAN DC: Prevention and management of cytomegalovirus infection in solid-organ transplantation. Expert Rev. Antiinfect Ther. (2007) 5(2):295-304.
15. HODSON EM, JONES CA, STRIPPOLI GF et al.: Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. (2007) (2):CD005129.
16. BIGGINS SW, TERRAULT NA: Management of recurrent hepatitis C in liver transplant recipients. Infect. Dis. Clin. North Am. (2006) 20(1):155-174.
17. SAMUEL D, MULLER R, ALEXANDER G et al.: Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. (1993) 329(25):1842-1847.
18. HANSH, OFMAN J, HOLT C et al.: An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplant. (2000) 6(6):741-748.
19. TEMESGEN Z, WARNKE D, KASTEN MJ: Current status of antiretroviral therapy. Expert Opin. Pharmacother. (2006) 7(12):1541-1554.
20. FALSEY AR, HENNESSEY PA, FORMICA MA et al.: Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. (2005) 352(17):1749-1759.
21. RUPPRECHT CE, WILLOUGHBY R, SLATE D: Current and future trends in the prevention, treatment and control of rabies. Expert Rev. Antiinfect Ther. (2006) 4(6):1021-1038.
22. FRIDKIN SK: The changing face of fungal infections in health care settings. Clin. Infect. Dis. (2005) 41(10):1455-1460. • Review of the medical importance of fungal infections.
23. CASADEVALL A, PIROFSKI L: Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr. Mol. Med. (2005) 5(4):421-433.
24. ORANGE JS, HOSSNY EM, WEILER CR et al.: Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J. Allergy Clin. Immunol. (2006) 117(4 Suppl.):S525-S553. •• Review of the role of IVIG in treating human diseases and evidence-based recommendations for its clinical use.
25. BOES M: Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. (2000) 37(18):1141-1149.
26. CASADEVALL A, PIROFSKI LA: A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. (2006) 91:1-44.
27. GETAHUN A, HEYMAN B: How antibodies act as natural adjuvants. Immunol. Lett. (2006) 104(1-2):38-45.
28. ROMANI L: Immunity to fungal infections. Nat. Rev. Immunol. (2004) 4(1):1-23.
29. READING SA, DIMMOCK NJ: Neutralization of animal virus infectivity by antibody. Arch. Virol. (2007) 152(6):1047-1059.
30. SATOH M, IIDA S, SHITARA K: Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. (2006) 6(11):1161-1173.
31. CASADEVALL A, GOLDSTEIN H, DADACHOVA E: Targeting host cells harbouring viruses with radiolabeled antibodies. Expert Opin. Biol. Ther. (2007) 7(5):595-597.
32. MOHAMED N, JONES SM, CASEY LS et al.: Heteropolymers: a novel technology against blood-borne infections. Curr. Opin. Mol. Ther. (2005b) 7(2):144-150.
33. TER MEULEN J, VAN DEN BRINK EN, POON LL et al.: Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. (2006) 3(7):E237.
34. RASMUSSEN SK, RASMUSSEN LK, WEILGUNY D et al.: Manufacture of recombinant polyclonal antibodies. Biotechnol. Lett. (2007) 29(6):845-852.
35. VAN NUNEN AB, BAUMANN M, MANNS MP et al.: Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver (2001) 21(3):207-212.
36. MUZZI A, MASIGNANI V, RAPPUOLI R: The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov. Today (2007) 12(11-12):429-439.
37. BURNIE J, CARTER T, RIGG G et al.: Identification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy. FEMS Immunol. Med. Microbiol. (2002) 33(3):179-189.
38. MEEHL M, HERBERT S, GOETZ F et al.: Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. (2007) 51(8):2679-2689.
39. CHOUDHRY V, ZHANG MY, DIMITROVA D et al.: Antibody-based inhibitors of HIV infection. Expert Opin. Biol. Ther. (2006) 6(5):523-531.
40. TRKOLA A, KUSTER H, RUSERT P et al.: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. (2005) 11(6):615-622. • First Phase I trial with combinations of HIV neutralizing mAbs.
41. MANRIQUE A, RUSERT P, JOOS B et al.: In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5 and 4E10. J. Virol. (2007) 81(16):8793-8808.
42. HELLE F, GOFFARD A, MOREL V et al.: The neutralizing activity of anti-HCV antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. (2007) 81(15):8101-8111.
43. NUIJTEN MJ, WITTENBERG W, LEBMEIER M: Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics (2007) 25(1):55-71.
44. WU H, PFARR DS, JOHNSON S et al.: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. (2007) 368(3):652-665.
45. JESTER PM, TILDEN SJ, LI Y et al.: Regulatory challenges: lessons from recent West Nile virus trials in the United States. Contemp. Clin. Trials (2006) 27(3):254-259.
46. NORRIS D, MORALES J, GODOFSKY E et al.: TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant vital load reduction and CD4 cell count increase when compared with OBR alone in Phase II study at 48 weeks. Int. Conf. AIDS (2006) 16:(Abstract No. ThLB0218).
47. MURGA JD, FRANTI M, PEVEAR DC et al.: Potent antivital synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2006) 50(10):3289-3296.
48. LALEZARI J et al.: A Phase I, dose-escalation, placebo-controlled study of a fully human monoclonal antibody (CCR5mAb004) against CCR5 in patients with CCR5-tropic HIV-1 infection. 46th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco (2006) (Abstract H-1668).
49. SHIBATA J, YOSHIMURA K, HONDA A et al.: Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. (2007) 81(8):3757-3768.
50. SCHIANO TD, CHARLTON M, YOUNOSSI Z et al.: Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a Phase II randomized study. Liver Transplant. (2006) 12(9):1381- 1389.
51. DAGAN S, EREN R: Therapeutic antibodies against viral hepatitis. Curr. Opin. Mol. Ther. (2003) 5(2):148-155.
52. SOARES M, SYED S, BARBERO G et al.: Antibody mediated targeting of "inside-out" anionic phospholipids in viral disease. J. Immunol. (2007) 178:47.21 (Meeting Abstract).
53. GALUN E, EREN R, SAFADI R et al.: Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology (2002) 35(3):673-679.
54. CARDENAS S, AUAIS A, PIEDIMONTE G: Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev. Anti Infect. Ther. (2005) 3(5):719-726.
55. CARBONELL X, LOSONSKY G, HULTQUIST M et al.: Phase III trial of motavizumab (MEDI-524), an enhanced potency respiratory syncytial virus (RSV) specific monoclonal antibody (Mab) for the prevention of serious RSV disease in high risk infants. Abstract [8220.9]. Ped. Acad. Soc. Ann. Meeting, Toronto, Canada (2007).
56. GOUDSMIT J, MARISSEN WE, WELDON WC et al.: Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. (2006) 193(6):796- 801.
57. MOHAMED N, CLAGETT M, LI J et al.: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. (2005a) 73(2):795-802.
58. SUBRAMANIAN GM, CRONIN PW, POLEY G et al.: A Phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis. (2005) 41(1):12-20.
59. VITALE L, BLANSET D, LOWY I et al.: Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. (2006) 74(10):5840-5847.
60. RIGG GP, MATTHEWS RC, DONOHOE MS et al.: Aurograb shows broad spectrum synergy with vancomycin against MRSA and VISA (vancomycin-intermediate) strains of Staphylococcus aureus. 42nd Interscience Conference Antimicrobial Agents Chemotherapy (ICAAC), (27-30 September 2002) 42:(Abstract No. E-1645).
61. THACKRAY H, LASSITER H, WALSH W et al.: Phase II randomized, double blind, placebo-controlled, safety, pharmacokinetics (PK), and clinical activity study in very low birth weight (VLBW) neonates of pagibaximab, a monoclonal antibody for the prevention of Staphylococcal infection. Pediatr. Res. (2006) 59(4).
62. WEEMS JJ Jr, STEINBERG JP, FILLER S et al.: Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. (2006) 50(8):2751-2755.
63. LANG AB, HORN MP, IMBODEN MA et al.: Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. Vaccine (2004) 6(22) (Suppl. 1):S44-S48.
64. FRANK DW, VALLIS A, WIENER-KRONISH JP et al.: Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV J. Infect. Dis. (2002) 86(1):64-73.
65. BABCOCK GJ, BROERING TJ, HERNANDEZ HJ et al.: Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. (2006) 74(11):6339-6347.
66. PACHL J, SVOBODA P, JACOBS F et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. (2006) 42(10):1404-1413.
67. DAVIS GL, NELSON DR, TERRAULT N et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (civacir) in liver transplant recipients. Liver Transplant. (2005) 11(8):941-949.
68. BENJAMIN DK, SCHELONKA R, WHITE R et al.: A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. (2006) 26(5):290-295.
69. VERNACHIO JH, BAYER AS, AMES B et al.: Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. (2006) 50(2):511-518.
70. BAKER M: Anti-infective antibodies: finding the path forward. Nat. Biotechnol. (2006) 24(12):1491-1493.
71. REICHERT JM: Trends in the development and approval of monoclonal antibodies for viral infections. Biodrugs (2007) 21(1):1-7.
72. REICHERT JM, DEWITZ MC: Anti-infective monoclonal antibodies: perils and promise of development. Nat. Rev. Drug Discov. (2006) 5(3):191-195.
73. HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23(9):1126-1136.
74. http://www.emea.europa.eu/pdfs/human/opinion/12972307en.pdf